Congressional Research Service: Legal Analysis of DEA Emergency Scheduling of Kratom Compound 7-OH

Why it matters

Congress now has a formal legal analysis to guide potential legislative action on kratom—either to accelerate permanent scheduling of 7-OH or to establish a separate consumer protection framework for botanical kratom. The CRS analysis clarifies exactly which products would become federal crimes to possess or sell if the temporary order takes effect August 5, 2026.

The big picture

The DEA's July 1, 2026 notice of intent to temporarily schedule 7-hydroxymitragynine (7-OH) above a 0.05% threshold, plus three synthetic derivatives (mitragynine pseudoindoxyl, MGM-15, MGM-16), marks the most significant federal action on kratom since a withdrawn 2016 scheduling attempt. The Congressional Research Service was tasked with analyzing the legal framework because Congress is weighing whether to codify, expand, or counter DEA's move. A parallel bill—the END 7-OH Act (H.R. 8000)—would permanently add 7-OH to Schedule I without relying on DEA's temporary authority.

Key findings

• DEA's temporary scheduling order is expected to take effect on or after August 5, 2026, and would remain in force for up to two years with a possible one-year extension
• The 0.05% 7-OH threshold targets concentrated commercial products; botanical kratom with naturally occurring 7-OH below that level would NOT be scheduled
• All three synthetic 7-OH-related substances (mitragynine pseudoindoxyl, MGM-15, MGM-16) would be fully scheduled with no threshold—any amount would be Schedule I
• Handling these substances outside federally approved research after scheduling takes effect would constitute a federal criminal offense
• Congress could enact the END 7-OH Act to make scheduling permanent, or separately pass the Federal Kratom Consumer Protection Act to create an FDA-led regulatory framework for botanical kratom

What they say

The CRS report states that "if the temporary scheduling orders are issued and take effect as planned, 7-OH above the specified threshold, MP, MGM-15, and MGM-16 would be legally treated as Schedule I controlled substances for the duration of the temporary scheduling" and that "handling these substances outside the context of federally approved research studies would be a federal crime."

Bottom line

The DEA's August 5, 2026 scheduling deadline will make concentrated 7-OH products and three synthetic derivatives federal Schedule I controlled substances—while leaving botanical kratom below the 0.05% threshold unaffected—unless Congress intervenes.